Expertise in
3
conditions

Judith Ragg-Loffler

Natters, AT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
Natters, AT 

Overview

Judith Ragg-Loffler practices in Natters, Austria. Ms. Ragg-Loffler is highly rated in 3 conditions, according to our data. Her top areas of expertise are Long Haul COVID, COVID-19, Severe Acute Respiratory Syndrome (SARS), and Langerhans Cell Histiocytosis.

Her clinical research consists of co-authoring 82 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Natters, 6161, Austria
Other Locations
Innsbruck, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Connective Tissue Diseases and Lung Manifestations Prospective Trial With Focus on Systemic Sclerosis (Colipris)
Connective Tissue Diseases and Lung Manifestations Prospective Trial With Focus on Systemic Sclerosis (Colipris)
Enrollment Status: Recruiting
Publish Date: May 27, 2020
Intervention Type: Biological, Diagnostic test
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
View 1 Less Clinical Trial

82 Total Publications

Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer.
Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer.
Journal: Pharmaceutics
Published: December 23, 2025

Frequently Asked Questions about Judith Ragg-Loffler

Is Judith Ragg-Loffler a top-rated expert for Long Haul COVID?

MediFind is an objective health platform that identifies experts based on real-world data. Judith Ragg-Loffler is classified as an Advanced expert for Long Haul COVID, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Judith Ragg-Loffler participate in research or clinical trials?

Yes. Judith Ragg-Loffler has published 82 articles and abstracts on conditions like Long Haul COVID. You can view a list of Judith Ragg-Loffler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ragg-Loffler's expertise for a condition
ConditionClose
      View All 30 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile